ProCE Banner Activity

Practical Application of Immuno-Oncology in RCC: Expert Discussion of Frontline Therapy

Podcast Episodes
Listen to Elizabeth R. Plimack, MD, MS; Brian A. Costello, MD; and Martin H. Voss, MD, discuss current best practices for first-line immunotherapy treatment of advanced renal cell carcinoma.

Released: August 31, 2020

Expiration: August 30, 2021

No longer available for credit.

Share

Faculty

Elizabeth Plimack

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Brian A. Costello

Brian A. Costello, MD, MS

Associate Professor of Oncology and Urology
Consultant

Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Martin H. Voss

Martin H. Voss, MD

Attending Physician
Division of GU Medical Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
Assistant Professor

Weill Cornell Medical College
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from
Eisai
Pfizer and EMD Serono

Supported by a medical education grant from
Exelixis, Inc.
Supported by an independent educational grant from

Merck Oncology

Partners

NCCN

ProCE Banner

Program Director Disclosure

Program Director

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, has disclosed that she has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Flatiron, Genentech, Janssen, Merck, Pfizer, and Seattle Genetics and funds for research support from Astellas, Bristol-Myers Squibb, Genentech, and Merck.

Faculty Disclosure

Primary Author

Brian A. Costello, MD, MS

Associate Professor of Oncology and Urology
Consultant

Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Martin H. Voss, MD

Attending Physician
Division of GU Medical Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
Assistant Professor

Weill Cornell Medical College
New York, New York

Martin H. Voss, MD, has disclosed that he has received consulting fees from Calithera, Corvus, Eisai, Exelixis, GlaxoSmithKline, Novartis, and Pfizer; funds for research support from Bristol-Myers Squibb, Genentech, and Pfizer; and fees for non-CME/CE services from AstraZeneca, Eisai, and Takeda.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has disclosed that his spouse has ownership interest (stock) in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.